George Tidmarsh resigned as director of FDA’s Center for Drug Evaluation and Research after being placed on administrative leave amid an internal probe into his conduct, according to reporting in Bloomberg and STAT. The personnel moves followed a period of high‑profile departures, policy reversals and public disputes within the agency. Observers and industry sources told STAT the sequence of events has raised concerns about the agency’s stability and impartiality. The episode places added scrutiny on pending reviews, novel approval pathways and high‑stakes drug decisions. Companies with near‑term submissions and sponsors relying on regulatory predictability face increased uncertainty as leadership turnover prompts fresh policy reviews and internal investigations.